CD22 on the human basophils bind differently to anti-CD22 of different manufacturers

We reported that human basophils express CD22 without expression of CD19 (1). Several scientists reported to us that they could not label the basophils using monoclonal antibodies to CD22 (anti-CD22). Therefore, we studied if there are any differences between antibodies provided by different manufacturers. The anti-CD22 showed different results depending on the manufacturers that we used. Anti-CD22 (Becton Dickinson Immunocytometry Systems, San Jose, CA) labeled the basophils well. Anti-CD22 (clone RFB4) from Novocastra Laboratories (Peterborough, UK) and anti-CD22 (clone MYG13) from Neomarkers (Fremont, CA) also bound well to the basophils. However, anti-CD22 from several other companies (Dako, Copenhagen, Denmark; PharMingen, San Diego, CA) did not bind human basophils. All of them bound to the human B cells very well. Therefore, only antibodies that bind to the basophils should be selected to sort human basophils using this technique. Maybe because of this reason, some authors reported that the basophils were CD22 negative or CD33 negative (2, 3). We hope that further study on the difference of these antibodies could result in the production of a new basophil-specific (not B cells) antibody.